"A hypothesis should not be a fixed concept, it should change and evolve based on data and new findings and as scientists, we should constantly challenge our hypotheses."
I am a principal scientist and a group leader at the Cell Culture and Bioprocess Operations (CCBO) department at Genentech. I joined the CCBO department in 2010, after completing my postdoctoral work here at Genentech in Physiological Chemistry department under supervision of Dr. Vishva Dixit.
My educational background is as following:
As a current postdoc mentor and previous Genentech postdoc, I am very proud of our postdoc program. Every postdoc brings with himself/herself new and exciting ways to look at and solve problems. Postdocs want to learn and discover and, in the process, they help us to think and look outside of the box. I truly enjoy interacting with these brilliant minds and believe that as mentors we should foster, support, and supervise them so that they become independent and confident researchers, as they will be leading our science into the future.
J Cell Biol. 2020 Jul 6;219(7):e201908087. doi: 10.1083/jcb.201908087
Biotechnol J. 2019 Apr;14(4):e1800332. doi: 10.1002/biot.201800332
Louie S, Haley B, Marshall B, Heidersbach A, Yim M, Brozynski M, Tang D, Lam C, Petryniak B, Shaw D, Shim J, Miller A, Lowe JB, Snedecor B, Misaghi S.
Providing medicine at low(er) cost is an unmet challenge especially with regards to protein based therapeutic molecules. Improving expression and titer of cell lines that are used to manufacture these therapeutic molecules is hence of great interest. My team studies Chinese hamster ovary (CHO) cells behavior in culture at molecular and cellular levels, aiming to identify and utilize key proteins and signaling pathways that can potentially increase protein expression or culture growth. We regularly use biochemical and genetic screening tools to study and advance our understanding of CHO protein expression platforms. We are also involved in generation of stable cell lines expressing bio-therapeutics (proteins and antibodies) that support phase-I to phase-III and commercial drug manufacturing stages.